Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 9.22% (Institutional Shares) in the quarter compared to a 3.44% gain for the Russell 3000 Health Care Index (benchmark) and an 8.74% gain for the S&P 500 Index. Since its inception, on April 30, 2018, the fund gained 13.58% on an annualized basis, compared to the benchmark’s 10.85% gain and the S&P 500 Index’s 12.54% return. Favorable stock selection led the fund to outperform in the quarter. Investments in biotechnology, pharmaceuticals, and healthcare equipment accounted for most of the relative gains of the fund in the quarter. In addition, please check the fund’s top five holdings to know its best picks in 2023.
Baron Health Care Fund highlighted stocks like EElevance Health, Inc. (NYSE:ELV) in the second quarter 2023 investor letter. Headquartered in Indianapolis, Indiana, Elevance Health, Inc. (NYSE:ELV) is a health benefits company. On July 24, 2023, Elevance Health, Inc. (NYSE:ELV) stock closed at $471.16 per share. One-month return of Elevance Health, Inc. (NYSE:ELV) was 5.99%, and its shares gained 0.47% of their value over the last 52 weeks. Elevance Health, Inc. (NYSE:ELV) has a market capitalization of $111.028 billion.
Baron Health Care Fund made the following comment about Elevance Health, Inc. (NYSE:ELV) in its second quarter 2023 investor letter:
“These positive effects were somewhat offset by adverse stock selection in managed health care, where the Fund’s investments in health insurance leaders Humana Inc. and Elevance Health, Inc. (NYSE:ELV) were a modest drag on performance. Humana and Elevance Health were down during the quarter because of commentary from UnitedHealth Group Incorporated management indicating that medical cost trends were running at the high end of their guidance driven by higher levels of outpatient medical activity, particularly among Medicare patients. We think UnitedHealth, Humana, and Elevance will be able to manage through an uptick in medical cost trends, but we modestly reduced our positions in Humana and Elevance due to the potential impact on earnings.
We continue to own UnitedHealth, Humana Inc., and Elevance Health, Inc. because we believe these companies will be able to manage through this period without a material earnings impact, but we did modestly reduce our positions in Humana and Elevance Health.”
Source: Unsplash
Elevance Health, Inc. (NYSE:ELV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 81 hedge fund portfolios held Elevance Health, Inc. (NYSE:ELV) at the end of first quarter which was 75 in the previous quarter.
We discussed Elevance Health, Inc. (NYSE:ELV) in another article and shared Madison Investors Fund’s views on the company. In addition, please check out our hedge fund investor letters Q2 2023 page for more investor letters from hedge funds and other leading investors.
Suggested Articles:
- 10 Best Steel Stocks to Invest In
- 20 Easiest Countries to Adopt a Baby From
- 12 Most Luxurious Cruise Lines
Disclosure: None. This article is originally published at Insider Monkey.
